Hohl Corinne Michèle, Sadatsafavi Mohsen, Nosyk Bohdan, Anis Aslam Hayat
Division of Emergency Medicine, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada.
Acad Emerg Med. 2008 Jan;15(1):1-8. doi: 10.1111/j.1553-2712.2007.00022.x.
To synthesize the evidence comparing the adverse event (AE) profile and clinical effectiveness of midazolam and propofol for procedural sedation (PS) in adults in the emergency care setting.
The authors conducted a systematic review of randomized controlled trials (RCTs) and observational studies reporting the use of either midazolam and/or propofol for adult PS in the emergency department (ED). A systematic search strategy was developed and applied to six bibliographic reference databases. Three emergency medicine journals, the Canadian Adverse Drug Reaction Newsletter, and conference proceedings were hand-searched. Retrieved articles were reviewed and data were abstracted using standardized data collection. Trial quality was assessed using the Jadad score. The outcomes assessed were the proportion of patients with AEs and the pooled mean difference in the proportion of patients with successful PS.
Of 229 articles identified, 28 met the inclusion criteria for the analysis of AEs. Only one major AE to PS was found, resulting in no statistically significant difference in the proportion of major AEs between agents. Four studies were RCTs that met the inclusion criteria for the analysis of clinical effectiveness. Two trials met criteria for good quality. The RCTs enrolled between 32 and 86 patients, and the most common indications for PS were orthopedic reductions and cardioversions. There was a nonsignificant difference in the proportion of patients with successful PS in favor of propofol (effect difference 2.9%, 95% confidence interval (CI) = -6.5 to 15.2).
The authors found no significant difference in the safety profile and the proportion of successful PS between midazolam and propofol for adults in the ED.
综合比较咪达唑仑和丙泊酚在急诊环境中用于成人程序性镇静(PS)时的不良事件(AE)情况及临床疗效的证据。
作者对报告在急诊科(ED)使用咪达唑仑和/或丙泊酚进行成人PS的随机对照试验(RCT)和观察性研究进行了系统评价。制定了系统检索策略并应用于六个文献参考数据库。对三种急诊医学期刊、《加拿大药物不良反应通讯》和会议论文集进行了手工检索。对检索到的文章进行评审,并使用标准化数据收集方法提取数据。使用Jadad评分评估试验质量。评估的结局指标为发生AE的患者比例以及PS成功患者比例的合并平均差。
在识别出的229篇文章中,28篇符合AE分析的纳入标准。仅发现1例与PS相关的严重AE,两种药物之间严重AE的比例无统计学显著差异。四项研究为符合临床疗效分析纳入标准的RCT。两项试验符合高质量标准。RCT纳入了32至86例患者,PS最常见的适应证为骨科复位和心脏复律。PS成功患者比例方面,丙泊酚有优势,但差异无统计学意义(效应差值2.9%,95%置信区间(CI)=-6.5至15.2)。
作者发现,在ED中,咪达唑仑和丙泊酚用于成人时,安全性及PS成功比例方面无显著差异。